Gan & Lee Pharmaceutical
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A leading integrated biopharma company focused on insulin analogs and diabetes therapies.
Metabolic
Technology Platform
Fully integrated platform for the development and large-scale GMP manufacturing of biosynthetic insulin analogs and other recombinant protein therapeutics.
Opportunities
Significant opportunity in the vast Chinese diabetes market and in expanding its innovative pipeline (e.g., GLP-1) to capture higher value.
Risk Factors
Exposed to ongoing insulin pricing pressures and volume-based procurement policies in China, which could erode margins on core products.
Competitive Landscape
Faces intense competition in the large but price-sensitive diabetes market from multinational pharma and other domestic manufacturers like Tonghua Dongbao.